STOCK TITAN

Ionis HR chief Devers sells 1,357 shares for taxes

The sale covered required tax withholding, and the restricted stock units vest in four equal annual installments.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Shannon L. Devers, EVP, Chief Human Resources Ofc at Ionis Pharmaceuticals Inc. (IONS), acquired 2,820 common shares when restricted stock units vested and were released on October 15, 2026. On October 16, she sold 1,357 common shares at a weighted average price of $43.5386 per share through an automatic sale to cover required tax withholding; no Rule 10b5-1 plan is reported. Her reported post-transaction RSU position was 49,884 units.

Insider Devers Shannon L.
Role EVP, Chief Human Resources Ofc
Sold 1,357 shs ($59K)
Approx. gross sale proceeds $59K
Approx. exercise cost $0.00
Type Security Shares Price Value
Sale Common Stock F2, F3 1,357 $43.5386 $59K
Exercise Restricted Stock Unit F4, F5 2,820 $0.00 $0.00
Exercise Common Stock F1 2,820 $0.00 $0.00
Holdings After Transaction: Restricted Stock Unit — 49,884 contracts (Direct); Common Stock — 17,811 shares (Direct)
Footnotes (5)
  1. F1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
  2. F2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.1383 to $43.538918 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
  4. F4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
  5. F5. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Common shares sold 1,357 shares October 16, 2026; automatic sale to cover required tax withholding
Weighted average sale price $43.5386 per share Sale on October 16, 2026
Restricted stock units vested and released 2,820 units October 15, 2026
Reported RSUs after transaction 49,884 units Following the October 15, 2026 transaction
Sale price range $43.1383 to $43.538918 per share Shares sold in multiple transactions on October 16, 2026
RSU vesting schedule 4 equal annual installments Restricted Stock Units
Common shares represented by each RSU 1 common share, or its equivalent cash value Contingent right under each Restricted Stock Unit
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"automatic sale to cover the required tax withholding obligations"
2011 Equity Incentive Plan financial
"pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IONS shares did Shannon L. Devers sell, and at what price?

She sold 1,357 common shares on October 16, 2026, at a weighted average price of $43.5386 per share. The shares were sold in multiple transactions ranging from $43.1383 to $43.538918 per share through an automatic sale to cover required tax withholding.

How many IONS shares did Shannon L. Devers acquire?

Devers acquired 2,820 common shares on October 15, 2026, pursuant to vesting and release of a Restricted Stock Unit award. Each Restricted Stock Unit represents a contingent right to receive one Ionis common share or its equivalent cash value.

How do the IONS restricted stock units vest?

The restricted stock units vest in four equal annual installments. Upon vesting, they are paid in whole shares of Ionis common stock or cash, as the company may determine.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Devers Shannon L.

(Last)(First)(Middle)
2855 GAZELLE COURT

(Street)
CARLSBAD CALIFORNIA 92010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Human Resources Ofc
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/15/2026M(1)2,820(1)A$0.019,168D
Common Stock10/16/2026S(2)1,357(2)D$43.5386(3)17,811D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0.0(4)10/15/2026M2,820 (5) (5)Common Stock2,820$0.049,884D
Explanation of Responses:
1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.1383 to $43.538918 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
5. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers10/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading